 This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer CRPC who have failed one or two chemotherapy regimens. At least one of the previous chemotherapies must have contained docetaxel. 